4% lower revenue,Less than 2% annual sales cancelled,Less than 5% annual sales delayedUnderlying EBITDA more than current market cap,Directors bought high 30sDropped from 40 to 10c is not justified.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025